JD Health (06618) announced interim results, profit attributable to shareholders of 3.437 billion yuan, an increase of 32.37% year-on-year

According to the Zhitong Finance App, JD Health (06618) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 40.888 billion (same unit), an increase of 15.9%; non-IFRS operating profit for the period was RMB 3.483 billion, up 40.3% year on year; profit attributable to the company's owners was RMB 3.437 billion, up 32.37% year on year; basic profit per share.

In the first half of 2026, the country will continue to promote the high-quality development of the healthcare industry. The State Council issued the “Fifteenth Five-Year Plan” to expand consumption, which clearly supports healthy consumption, vigorously develops new service formats such as health management, and opens up room for long-term growth in the industry from the demand side. At the same time, the National Health Commission's “Implementation Opinions on Promoting and Standardizing the Development of “Artificial Intelligence+Healthcare” applications further promoted the R&D and application of vertical industrial models and medical agents, and provided policy support for technology-driven service innovation. The industry standardization process has accelerated, and the value of full-link supply chain layout and compliance operation capabilities has been further highlighted, creating a favorable industry environment for JD Health to continue to strengthen its competitive advantage and expand long-term growth space.

During the reporting period, JD Health relied on the core capabilities of the pharmaceutical supply chain, further consolidated user mentality, and continued to strengthen its leading edge in industry scale. In the first half of 2026, the company achieved total revenue of RMB 40.9 billion, up 15.9% year on year; non-IFRS operating profit of RMB 3.5 billion, up 40.3% year on year, and non-IFRS operating profit margin increased from 7.0% to 8.5%.

As an industry-leading healthcare service company, JD Health continues to implement a long-term business strategy around “experience, cost, and efficiency” to drive business growth and continuous improvement of profits. The company actively promotes the integration of self-operated supply chain capabilities and medical services, deepens cooperation with industry chain partners, and steadily promotes the application of AI in diverse health consumption scenarios. In the future, JD Health will focus on user needs, continue to expand the boundaries of online and offline health services, and provide users with easy to obtain, convenient, high-quality and affordable health products and digital intelligent health solutions.